CBLL (CeriBell) Cash Flow from Financing: $6.68 Mil (TTM As of Mar. 2026)


CBLL CeriBell Inc CBLL
12 GF Score
Price $19.54
! 4 Warning Signs
View Full Analysis

What is CeriBell Cash Flow from Financing?

CeriBell CBLL -2.25% 12 Cash Flow from Financing is $6.68 Mil as of Mar. 2026. GuruFocus rates CBLL with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2026, CeriBell paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, CeriBell spent $0.00 Mil on financial activities for the three months ended in Mar. 2026.


CeriBell  (NAS:CBLL) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

CeriBell's issuance of stock for the three months ended in Mar. 2026 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

CeriBell's repurchase of stock for the three months ended in Mar. 2026 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

CeriBell's net issuance of debt for the three months ended in Mar. 2026 was $0.00 Mil. CeriBell received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

CeriBell's net issuance of preferred for the three months ended in Mar. 2026 was $0.00 Mil. CeriBell paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

CeriBell's cash flow for dividends for the three months ended in Mar. 2026 was $0.00 Mil. CeriBell received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

CeriBell's other financing for the three months ended in Mar. 2026 was $0.00 Mil. CeriBell received $0.00 Mil on other financial activities.


CeriBell Cash Flow from Financing Related Terms


CeriBell Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for CeriBell's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CeriBell Cash Flow from Financing Chart

CeriBell Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Cash Flow from Financing
49.81 -2.82 196.52 5.05

CeriBell Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.01 1.64 1.40 1.63
CBLL
12GF Score
CeriBell Inc CBLL
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CeriBell Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

CeriBell's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:

CeriBell's Cash from Financing for the quarter that ended in Mar. 2026 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of $6.68 Mil mean?
CeriBell (CBLL) has a Cash Flow from Financing of $6.68 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CeriBell and its competitors.
Is CeriBell's Cash Flow from Financing too high?
CeriBell's current Cash Flow from Financing is $6.68 Mil. Overall, CeriBell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CeriBell's Cash Flow from Financing compare to BBNX and SIBN?
CeriBell's Cash Flow from Financing of $6.68 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CeriBell and its competitors. CeriBell's current Cash Flow from Financing is $6.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CeriBell stock overvalued right now?
CeriBell (CBLL) has a current Cash Flow from Financing of $6.68 Mil. The current Cash Flow from Financing is $6.68 Mil. CeriBell's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For CeriBell (CBLL), the current Cash Flow from Financing is $6.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CeriBell Business Description

Address 360 N. Pastoria Avenue, Sunnyvale, CA, USA, 94085
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
12GF Score

Get the complete analysis for CBLL

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.54
Price